Analysis of nationwide availability of negotiated drugs in China’s National Reimbursement Drug List

According to the WHO/HAI standards, the overall availability of negotiated drugs in China remains relatively low, with notable institutional stratification and regional disparities. This finding suggests that policy efforts should focus on strengthening supply incentives and promoting rational drug use. Additionally, policymakers should consider the differences across regions and institutions when advancing drug availability to ensure equitable access to medicines.